Skip to main content

Table 6 Twenty-one patients with positive anti-ds-DNA Abs after IFX

From: Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study

   anti-DNA ANA     
  age/sex before after before after EULAR response symptoms IFX following biologics
1 51/F < 2 300 40 320 No   Discontinue ADA- > TOC*4
2 41/F 6 300 320 320 No   Discontinue ETN
3 45/F 51 300 160 320 No SLE like*1 Discontinue ETN
4 32/F NA 52 320 1280 No    
5 31/F 5 42 80 160 No SLE like*2 Discontinue ETN
6 36/F 5 38 40 1280 No- > good   PSL 20 mg iv*3  
7 43/F 4 26 160 640 No   Discontinue TOC
8 56/F 3 26 80 160 No- > good   PSL 20 mg iv*3  
9 62/M 21 25 80 80 Good PCP Discontinue TOC
10 65/F 2 23 160 160 No   Discontinue TOC- > ETN*5
11 52/F NA 22 NA 160 No    
12 56/M < 2 20 320 320 No allergy Discontinue ETN
13 33/F 5 19 40 80 No    
14 51/F < 2 13 40 80 Mod    
15 56/M < 2 11 160 160 No- > mod   PSL 20 mg iv*3  
16 75/F < 2 11 < 40 320 No   Discontinue ETN
17 58/F 11 11 80 640 Mod    
18 30/M < 2 10 80 80 No   Discontinue ETN
19 35/F < 2 10 80 80 Good    
20 40/F 3 8 80 160 No   Discontinue ETN
21 59/F NA 7 NA 640 Mod    
  1. anti-DNA, anti-ds-DNA antibodies; ANA, antinuclear antibodies; IFX, infliximab; SLE, systemic lupus erythematosus; PCP; pneumocystis jirovecii pneumonia; PSL, prednisolone; iv, intravenous injection; ADA, adalimumab; ETN, etanercept; TOC, tocilizumab; *1, leukocytopenia and alopecia; *2, erythema; *3, premedication of each IFX administration; *4, ADA was also getting no response and successful swiched to TOC; *5, TOC ineffective, and ETN effective